Production of antitumor T-cells in tumor-bearing mice treated with tumor vaccine and 6-mercaptopurine.
Treatment with both L1210 murine leukemia cell vaccine (L1210 vaccine) and 6-mercaptopurine (6-MP) induced antitumor effector cells in the spleen and peritoneal cavity of L1210-bearing mice. The in vivo neutralization test showed that the spleen cells and peritoneal cells of mice treated with both agents, but not with either agent alone, prolonged the life span of animals simultaneously inoculated i.p. with live L1210 cells. These results indicate that these antitumor cells were associated with the augmented therapeutic response in L1210-bearing mice treated with both agents. The neutralizing activity of peritoneal cells was located to a fraction not adhering to plastic flasks and abolished by the treatment of anti-Thy 1.2 antibody and complement, indicating that they were T-cells. The in vitro antiproliferation test confirmed these observations. The spleen cells and peritoneal T-cells of these mice suppressed L1210 proliferation. Their activity was tumor specific since they suppressed the in vitro proliferation of L1210 but not P388 and L5178Y cells. The in vivo association of antitumor T-cells with the augmented therapeutic effect was substantiated by the finding that rabbit anti-mouse thymocyte globulin abolished the induced therapeutic effect.
D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002455:Cell Division; D007518:Isoantibodies / Q000276:immunology; D007939:Leukemia L1210 / Q000276:immunology* / Q000628:therapy; D015122:Mercaptopurine / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D013601:T-Lymphocytes / Q000276:immunology*; D014612:Vaccines / Q000276:immunology*
D000961:Antilymphocyte Serum; D007518:Isoantibodies; D014612:Vaccines; C035678:anti-Thy antibody; D015122:Mercaptopurine